Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025
Protagonist Therapeutics (PTGX) has announced its participation in the upcoming Jefferies Global Healthcare Conference, scheduled for June 3-5, 2025, in New York. The company's President and CEO, Dinesh V. Patel, Ph.D., will deliver a company overview presentation on Wednesday, June 4, at 1:25 P.M. ET.
The presentation will be available via webcast, and the company will also engage in one-on-one meetings during the conference. Interested parties can access the presentation replay on the Company's Investor Relations Events and Presentations webpage for one year following the event.
Protagonist Therapeutics (PTGX) ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference, che si terrà dal 3 al 5 giugno 2025 a New York. Il Presidente e CEO dell'azienda, Dinesh V. Patel, Ph.D., terrà una presentazione panoramica sull'azienda mercoledì 4 giugno alle 13:25 ET.
La presentazione sarà disponibile in webcast e la società parteciperà anche a incontri individuali durante la conferenza. Gli interessati potranno rivedere la presentazione nella sezione Eventi e Presentazioni per gli Investitori sul sito dell'azienda per un anno dopo l'evento.
Protagonist Therapeutics (PTGX) ha anunciado su participación en la próxima Jefferies Global Healthcare Conference, que se celebrará del 3 al 5 de junio de 2025 en Nueva York. El presidente y CEO de la compañía, Dinesh V. Patel, Ph.D., realizará una presentación general de la empresa el miércoles 4 de junio a la 1:25 p.m. ET.
La presentación estará disponible vía webcast y la compañía también participará en reuniones individuales durante la conferencia. Las partes interesadas podrán acceder a la repetición de la presentación en la página web de Eventos y Presentaciones para Inversores de la compañía durante un año después del evento.
Protagonist Therapeutics (PTGX)는 2025년 6월 3일부터 5일까지 뉴욕에서 열리는 Jefferies Global Healthcare Conference에 참여한다고 발표했습니다. 회사의 사장 겸 CEO인 Dinesh V. Patel, Ph.D.가 6월 4일 수요일 오후 1시 25분(동부 시간)에 회사 개요 발표를 진행할 예정입니다.
발표는 웹캐스트를 통해 제공되며, 회사는 컨퍼런스 기간 동안 일대일 미팅도 진행할 예정입니다. 관심 있는 분들은 행사 후 1년간 회사 투자자 관계 이벤트 및 발표 웹페이지에서 발표 영상을 다시 볼 수 있습니다.
Protagonist Therapeutics (PTGX) a annoncé sa participation à la prochaine Jefferies Global Healthcare Conference, qui se tiendra du 3 au 5 juin 2025 à New York. Le président-directeur général de la société, Dinesh V. Patel, Ph.D., présentera un aperçu de l'entreprise le mercredi 4 juin à 13h25 (heure de l'Est).
La présentation sera accessible en webcast, et la société participera également à des réunions individuelles pendant la conférence. Les personnes intéressées pourront revoir la présentation sur la page Événements et Présentations des Relations Investisseurs de la société pendant un an après l'événement.
Protagonist Therapeutics (PTGX) hat seine Teilnahme an der bevorstehenden Jefferies Global Healthcare Conference angekündigt, die vom 3. bis 5. Juni 2025 in New York stattfindet. Der Präsident und CEO des Unternehmens, Dinesh V. Patel, Ph.D., wird am Mittwoch, den 4. Juni, um 13:25 Uhr ET eine Unternehmensübersicht präsentieren.
Die Präsentation wird per Webcast verfügbar sein, und das Unternehmen wird während der Konferenz auch Einzelgespräche führen. Interessierte können die Aufzeichnung der Präsentation auf der Investor-Relations-Seite des Unternehmens für ein Jahr nach der Veranstaltung abrufen.
- None.
- None.
NEWARK, CA / ACCESS Newswire / May 21, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare Conference taking place June 3-5, 2025, in New York, NY. The Company will also participate in one-on-one meetings.
Jefferies Global Healthcare Conference - June 3-5, 2025
Format: Company Presentation
Day/Time: Wednesday, June 4 at 1:25 P.M. ET
Webcast: https://wsw.com/webcast/jeff319/ptgx/1883080
If you are interested in meeting with the Protagonist team during the conference, please reach out to your Jefferies representative.
A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage for one year following the event.
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides, icotrokinra and rusfertide, derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA expected in 2025. Icotrokinra (JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R") which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Following icotrokinra's joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at www.protagonist-inc.com.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
Media Contact
Virginia Amann, Founder/CEO
+1 833 500 0061 ext 1
ENTENTE Network of Companies
virginiaamann@ententeinc.com
SOURCE: Protagonist Therapeutics
View the original press release on ACCESS Newswire
FAQ
When is Protagonist Therapeutics (PTGX) presenting at the Jefferies Healthcare Conference 2025?
Who will represent PTGX at the Jefferies Healthcare Conference 2025?
How can investors access PTGX's Jefferies Conference presentation?
How can investors arrange meetings with Protagonist Therapeutics at the conference?
